Biohaven Pharmaceutical Holding Co. Ltd.
www.biohavenpharma.com
Latest From Biohaven Pharmaceutical Holding Co. Ltd.
Biohaven Taking Troriluzole Into Phase III OCD Study Despite Phase II/III Miss
After a prior failure in treating anxiety, the company believes the glutamate modulator showed signs of efficacy in obsessive-compulsive disorder that are worth pursuing, including at a higher dose.
Royalty Pharma Nears Biopharma Record Take With $2.18bn IPO
Company specializing in trading upfront cash for downstream earnings makes its public debut with largest IPO of 2020, and the second largest ever in biopharma.
Commercial Models Shifting As Pharma Mulls Digital-First Launches
Pharma is assessing digital-first launch strategies amid COVID-19 while a resizing of sales forces and the emergence of "digital orchestrators" may also be in store, the co-founder of healthcare solutions provider Indegene tells Scrip.
Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Company Information
- Industry
-
Biotechnology
- Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Neurology, Nervous System
- Alias(es)
- Biohaven Pharmaceuticals
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Biohaven Pharmaceutical Holding Co. Ltd.
- Senior Management
-
Vlad Coric, MD, CEO
Jim Engelhart, CFO
Robert Berman, MD, CMO
John Tilton, Chief Commercial Officer
Charlie Conway, PhD, CSO
Elyse Stock, MD, Chief, Portfolio Strategy & Dev.
Donnie McGrath, MD, Chief, Corp. Strategy & Bus. Dev.
Kim Gentile, VP, Operations - Contact Info
-
Biohaven Pharmaceutical Holding Co. Ltd.
Phone: (203) 404-0410
234 Church St.
New Haven, CT 06510
USA